TrippBio

TrippBio is a biotechnology company dedicated to developing breakthrough treatments for the initial targets of viral infections that have caused the global COVID-19 pandemic. TrippBio is developing TD213, a repurposed FDA-approved drug with a pending patent application. TD213 works by blocking the replication of the SARS-CoV-2 virus as well as the associated acute inflammatory response to the infection. TrippBio was founded based on the research of Dr. Ralph Tripp.